Currently, there are 60.68M common shares owned by the public and among those 59.25M shares have been available to trade.
The company’s stock has a 5-day price change of -29.63% and -17.25% over the past three months. CRMD shares are trading -9.38% year to date (YTD), with the 12-month market performance up to 88.21% higher. It has a 12-month low price of $3.61 and touched a high of $13.85 over the same period. CRMD has an average intraday trading volume of 1.01 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -28.67%, -31.74%, and -11.23% respectively.
Institutional ownership of CorMedix Inc (NASDAQ: CRMD) shares accounts for 37.73% of the company’s 60.68M shares outstanding.
It has a market capitalization of $445.37M and a beta (3y monthly) value of 1.37. The earnings-per-share (ttm) stands at -$0.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.30% over the week and 7.34% over the month.
Analysts forecast that CorMedix Inc (CRMD) will achieve an EPS of 0.18 for the current quarter, 0.12 for the next quarter and 1.28 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.07 while analysts give the company a high EPS estimate of 0.07. Comparatively, EPS for the current quarter was -0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 300.95%, and 136.21% over the next financial year.
Looking at the support for the CRMD, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on March 07, 2025, with the firm’s price target at $18. D. Boral Capital coverage for the CorMedix Inc (CRMD) stock in a research note released on January 13, 2025 offered a Buy rating with a price target of $15. Rodman & Renshaw was of a view on August 26, 2024 that the stock is Buy, while RBC Capital Mkts gave the stock Outperform rating on August 10, 2023, issuing a price target of $6. Needham on their part issued Buy rating on February 17, 2021.
